Summary
65 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥61.4B against ¥48.0B.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 7.3% a year over the last 3 years against 169% over 5 years.
- Out of every 100 JPY of revenue, only 3.7 JPY is left as net profit.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.5 JPY for 1 JPY of yearly profit. Over the last five years it was 16.0 JPY on average.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 169% a year over 5 years. Over the last 3 years it grew by 7.3% a year. For the next fiscal year analysts expect revenue to grow by 5.7%. Earnings per share grew by 8.8% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 JPY of revenue goes
- Cost of sales 75 JPY
- Sales and administration 20 JPY
- Taxes and other 1.2 JPY
- Net profit 3.7 JPY
Net profit, industry median (Medical - Pharmaceuticals) 4.8 JPY
Out of every 100 JPY of revenue, 3.7 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.98%
- Paid out of profit
- 49%
- Raised in a row
- 4 years
You receive $0.84 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly negative- Buy 0
- Hold 0
- Sell 1
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.